表紙
市場調査レポート

難治性急性骨髄性白血病:世界の治験レビュー

Refractory Acute Myeloid Leukemia Global Clinical Trials Review, H1, 2014

発行 GlobalData 商品コード 299734
出版日 ページ情報 英文 120 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
難治性急性骨髄性白血病:世界の治験レビュー Refractory Acute Myeloid Leukemia Global Clinical Trials Review, H1, 2014
出版日: 2014年04月15日 ページ情報: 英文 120 Pages
概要

当レポートでは、難治性急性骨髄性白血病の治療薬に関する治験について調査分析し、治験数および被験者数、段階別・相別の状況、有望企業、開発中の治療薬の情報、治験プロファイルなどを提供して、概略以下の構成でお届けいたします。

目次

イントロダクション

地域別の治験

  • 国別の治験動向
    • アジア太平洋地域の主要国
    • 欧州の主要国
    • 北米の主要国
    • 中東・アフリカの主要国
    • 中南米の主要国

G7諸国における治験:腫瘍科の治験に対する難治性急性骨髄性白血病の割合

G7諸国における治験:相別

G7諸国における治験:段階別

E7諸国における治験:腫瘍科の治験に対する難治性急性骨髄性白血病の割合

E7諸国における治験:相別

E7諸国における治験:段階別

相別の治験

段階別の治験

評価項目別の治験

未完了の治験

一定期間に採用された被験者

スポンサータイプ別の治験

有望なスポンサー

  • 難治性急性骨髄性白血病の治療薬の治験に参加している主要企業

有望薬

最新の治験ニュース

治験プロファイル

  • 主要企業の治験概要
    • Novartis AG
    • Pfizer Inc.
    • Celgene Corporation
    • Sanofi
    • C. H. Boehringer Sohn AG & Co. KG
    • Ambit Biosciences Corporation
    • F. Hoffmann-La Roche Ltd.
    • AROG Pharmaceuticals LLC
    • Amgen Inc.
    • AbbVie Inc.
  • 主要大学・研究機関・病院の治験概要
    • National Cancer Institute
    • Fred Hutchinson Cancer Research Center
    • Children's Oncology Group
    • The University of Texas M. D. Anderson Cancer Center
    • Stanford University
    • Washington University School of Medicine
    • Roswell Park Cancer Institute
    • Sidney Kimmel Comprehensive Cancer Center
    • Case Comprehensive Cancer Center

主な臨床プロファイル

付録

図表

目次
Product Code: GDHC2081CTIDB

GlobalData's clinical trial report, "Refractory Acute Myeloid Leukemia Global Clinical Trials Review, H1, 2014" provides data on the Refractory Acute Myeloid Leukemia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Refractory Acute Myeloid Leukemia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Refractory Acute Myeloid Leukemia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Refractory Acute Myeloid Leukemia
    • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Refractory Acute Myeloid Leukemia to Oncology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Refractory Acute Myeloid Leukemia to Oncology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Refractory Acute Myeloid Leukemia
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on Refractory Acute Myeloid Leukemia
    • Mar 12, 2014: Cornerstone Pharmaceuticals Lead Compound CPI-613 Demonstrates Ability to Disrupt Growth of Cancer Cells
    • Jun 25, 2013: FDA Issues Partial Clinical Hold On Cell Therapeutics's Tosedostat For Treatment Of Blood Cancer
    • Jun 13, 2013: Sunesis Pharma Announces Data And Safety Monitoring Board Recommends Continuation Of VALOR Trial With No Change To Study Conduct
    • Apr 01, 2013: Clavis Pharma Reports Negative Outcome Of Phase III CLAVELA Trial With Elacytarabine In Patients With Acute Myeloid Leukemia
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • Novartis AG
      • Clinical Trial Overview of Novartis AG
      • Pfizer Inc.
      • Clinical Trial Overview of Pfizer Inc.
      • Celgene Corporation
      • Clinical Trial Overview of Celgene Corporation
      • Sanofi
      • Clinical Trial Overview of Sanofi
      • C. H. Boehringer Sohn AG & Co. KG
      • Clinical Trial Overview of C. H. Boehringer Sohn AG & Co. KG
      • Ambit Biosciences Corporation
      • Clinical Trial Overview of Ambit Biosciences Corporation
      • F. Hoffmann-La Roche Ltd.
      • Clinical Trial Overview of F. Hoffmann-La Roche Ltd.
      • AROG Pharmaceuticals LLC
      • Clinical Trial Overview of AROG Pharmaceuticals LLC
      • Amgen Inc.
      • Clinical Trial Overview of Amgen Inc.
      • AbbVie Inc.
      • Clinical Trial Overview of AbbVie Inc.
    • Clinical Trial Overview of Top Institutes / Government
      • National Cancer Institute
      • Clinical Trial Overview of National Cancer Institute
      • Fred Hutchinson Cancer Research Center
      • Clinical Trial Overview of Fred Hutchinson Cancer Research Center
      • Children's Oncology Group
      • Clinical Trial Overview of Children's Oncology Group
      • The University of Texas M. D. Anderson Cancer Center
      • Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center
      • Stanford University
      • Clinical Trial Overview of Stanford University
      • Washington University School of Medicine
      • Clinical Trial Overview of Washington University School of Medicine
      • Roswell Park Cancer Institute
      • Clinical Trial Overview of Roswell Park Cancer Institute
      • Sidney Kimmel Comprehensive Cancer Center
      • Clinical Trial Overview of Sidney Kimmel Comprehensive Cancer Center
      • Case Comprehensive Cancer Center
      • Clinical Trial Overview of Case Comprehensive Cancer Center
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Region, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Europe, Top Five Countries, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, North America, Top Countries, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Central and South America, Top Countries, 2014*
  • Proportion of Refractory Acute Myeloid Leukemia to Oncology Clinical Trials, G7 Countries (%), 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Refractory Acute Myeloid Leukemia to Oncology Clinical Trials, E7 Countries (%), 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Phase, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials In Progress by Phase 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics, Global, Withdrawn Clinical Trials, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics, Global, Terminated Clinical Trials, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Refractory Acute Myeloid Leukemia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Celgene Corporation, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by C. H. Boehringer Sohn AG & Co. KG, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Ambit Biosciences Corporation, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by AROG Pharmaceuticals LLC, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by AbbVie Inc., 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Fred Hutchinson Cancer Research Center, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Children's Oncology Group, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Washington University School of Medicine, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Roswell Park Cancer Institute, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Sidney Kimmel Comprehensive Cancer Center, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Case Comprehensive Cancer Center, 2014*

List of Figures

  • Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Region (%), 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, North America, Top Countries (%), 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014*
  • Proportion of Refractory Acute Myeloid Leukemia to Oncology Clinical Trials, G7 Countries (%), 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Refractory Acute Myeloid Leukemia to Oncology Clinical Trials, E7 Countries (%), 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Phase (%), 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials In Progress by Phase, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Refractory Acute Myeloid Leukemia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • GlobalData Methodology
Back to Top